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The causative agents of acute respiratory infections in
children and adults are mostly thought to be viruses. Many
typesofvirusescouldcausesimilarsymptomsofARI.Among
them, inﬂuenza viruses A and B and respiratory syncytial
virus (RSV)are thought to be the most important because of
theseverityof illnessafterinfectionandtheirhighcommuni-
cability in the human population [1]. Type C inﬂuenza virus
usually is not serious and typically not included in discus-
sion about inﬂuenza infection [2]. In this article, discussion
is limited to inﬂuenza A and B only. These viruses belong to
the orthomyxoviridae family of viruses [3].
Inﬂuenza infects an estimated 120million people in the
United States, Europe, and Japan each year and is a major
causeofmorbidityandmortality.Inperiodsofﬂupandemics,
infection rates could be even higher. In the United States,out
of an estimated 20million cases of ﬂu each year,up to 40000
Americans die, and more than 400000 are hospitalized. The
resulting economic burden has been estimated to be as high
as $12billion. In the last few years, new developments in the
prevention, diagnosis, and treatment of inﬂuenza have been
introduced that will change the clinical milieu in the new
millennium.
The traditional vaccine approaches to the prophylaxis
have been problematic owing to the ability of these viruses to
undergo antigenic shift by exchanging genomic segments or
by undergoing antigenic drift, consisting of point mutations
in the surface glycoproteins haemagglutinin (HA)and neu-
raminidase(NA)genesasaresultofanerror-proneviralpoly-
merase.AntigenicshiftisseenonlyininﬂuenzaAvirusesand
occurswhenanovelHAorN Asubtypeisintroducedfroman
animal inﬂuenza virus reservoir into the human population.
Antigenic drift occurs in inﬂuenza A and B in and around
the antibody binding site. Therefore, the annual update of
inﬂuenza is necessary because of the annual occurrence of
antigenic drifts. For example, for the 1999–2000 season, it
was recommended that vaccines contain an A/Sydney/5/97
(H3N2)-like virus, an A/Beijing/262/95 (H1N1)-like virus,
and a B/Beijing/184/93-like virus or B/shangdong/7/97-like
virus. However, signiﬁcant morbidity and mortality were
clinically observed during this season, and indicated the ob-
vious limitations of this method of prevention. As a result of
these ongoing observations, other prevention and treatment
modalitieshavebeeninvestigatedandsomehavealreadybeen
introducedtopractice.Themostrecentbreakthroughinthat
direction is the introduction of neuraminidase inhibitors for
the treatment and prevention of inﬂuenza infection.
The neuraminidase is a surface glycoprotein that is com-
posed of eleven conserved residues [4] which catalyze the
cleavage of sialic acid residues terminally linked to glycopro-
teins and glycolipids and plays an important role in the repli-
cation of the virus. A recent new study demonstrated that
Tyr409 is the most critical residue for enzyme activity, and
that Asp149, Arg223, Glu275, and Arg374 also play impor-
tant roles in enzyme catalysis [2]. Neuraminidase function is
critical for the spread of virus to new cells,and if the enzyme
activity is inhibited, then virus infection is abrogated [2, 5].
Also,thereisevidencethatthisenzymeplayssomeroleinthe
introduction of apoptosis to the infected cells [6].
Currently, there are two neuraminidase inhibitors (NI)
available for clinical use: zanamivir and oseltamivir. In
phase II trials (NAIB2005 and NAIB2008), beneﬁt was seen
in early treatment (within 36hours of onset of illness).Viro-
logicalsubstudiesshowedmeanreductionsinvirusshedding
after 24hours of treatment of 1.5 to 2.0log [10] 50% tis-
sue culture infective doses compared with a placebo,with no
reemergence of virus after completion of the therapy [7, 8].
InphaseIIItrials,mediantimestoalleviationof majorsymp-
toms were reduced by up to 2.5days after treatment. Beneﬁt
of treatment in terms of time to return to normal activities,
reductions in consumption of acetaminophen, and the re-
ductions in the level of interference of inﬂuenza with sleep,
work,leisure,and recreational activities were reported [9].
In the prophylaxis trials, statistically signiﬁcant reduc-
tions in the incidence of inﬂuenza A was reported with the
use of inhaled zanamivir in a double blind study that in-
cluded 1107persons in two university communities [9, 10].
In this study, zanamivir was 67% efﬁcacious in preventing
laboratory-conﬁrmed clinical inﬂuenza and 84% efﬁcacious
inpreventinglaboratory-conﬁrmedillnesseswithfever.Also,
intravenous zanamvir (600mg twice daily for 5days)used
4hours prior to intranasal inoculation with infectious doses
of inﬂuenza A virus was successful in reducing the frequency
of viral shedding (0% versus 100% in placebo), serocon-
version (14% versus 100% in placebo), fever (14% versus90 Naem Shahrour 1:2 (2001)
88% in placebo), upper respiratory tract illness (0% versus
100% in placebo), and total symptom score (1% versus 44%
in placebo)[11]. Another trial showed that outbreak of in-
ﬂuenza A and B were prevented in a nursing home commu-
nity [9].
Oral administration of oseltamivir (GS4104)in two ran-
domizedtrials(1559subjectsgiven75mgonceortwicedaily)
[12] reduced the risk of infection during the inﬂuenza sea-
son from 4.8% in placebo to 1.2% and 1.3% in the treatment
groups. The protective effects of the drug were 74% in all
study sites combined and 84% in the areas where the rate of
inﬂuenza was higher. Another smaller study reached similar
conclusions [13].
The coadministration of NI with inactivated trivalent in-
ﬂuenzavaccinewasinvestigatedinEngland.Itwasfoundthat
itdoesnotadverselyaffecttheproductionof antihaemagglu-
tinin antibodies in the serum [14]. Finally, although ﬁght-
ing inﬂuenza seems like boxing a heavyweight champion and
odds are you will end up ﬂat on your back, but with proper
precautions and the development of new drugs you may be
able to avoid getting knocked out.
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